" class="no-js "lang="en-US"> Penn LDI - Medtech Alert
Wednesday, September 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Penn LDI | Pharmtech Focus

Penn LDI

About Penn LDI

Penn LDI
Founded in 1967, the Leonard Davis Institute of Health Economics at the University of Pennsylvania (Penn LDI) was the first academic institute of its kind, uniting the scholarly and clinical strengths of Penn’s leading business and medical schools. Over fifty years later, Penn LDI remains one of the most productive and influential health policy research groups in the nation. Penn LDI convenes experts from all of Penn’s twelve schools, the University of Pennsylvania Health System, and the Children’s Hospital of Philadelphia to address our most pressing health care challenges. Through strong translation, dissemination, and policy engagement strategies, LDI bridges the gap between research and policy, ensuring that sound research evidence reaches policymakers and informs key debates. We invite you to learn more and connect with us at ldi.upenn.edu and on Twitter @PennLDI.

Related Story

Diseases

 Monogram Health Donates $2.5M to University of Pennsylvania for Clinical Research Partnership Aimed at Improving Outcomes for People with Chronic Kidney Disease | Pharmtech Focus

Monogram Health Donates $2.5M to University of Pennsylvania for Clinical Research Partnership Aimed at Improving Outcomes for People with Chronic Kidney Disease

September 14 2022

Monogram Health, the leading value-based specialty provider of in-home nephrology, primary care, and benefit management […]